ALEC:NSD-Alector, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 10.99

Change

-0.30 (-2.66)%

Market Cap

USD 0.89B

Volume

1.02M

Average Target Price

USD 31.00 (+182.07%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer's disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Company Website : http://www.alector.com

Address : 131 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Employees : 153

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.99

52 Week High : 35.93

Short Ratio : 13.22

52 Week Low : 10.75

Shorted Shares : 8,428,750

200 Day Moving Average : 22.31

Shorted Shares Previous Month : 8,292,452

50 Day Moving Average : 12.93

Shares Held By Insiders : 173.99%

Short Percentage : 11.00%

Shares Held by Institutions : 62.32%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

 USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

 USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

 USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

 USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

 USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

 USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

 USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

 USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

 USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

 USD18.93B 47.64 35.20

ETFs Containing ALEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -36.22% 25% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -36.22% 25% F 21% F
Trailing 12 Months  
Capital Gain -23.79% 27% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.79% 27% F 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.22% N/A N/A 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.22% N/A N/A 60% D-
Risk Return Profile  
Volatility (Standard Deviation) 24.46% N/A N/A 60% D-
Risk Adjusted Return 37.70% N/A N/A 60% D-
Market Capitalization 0.89B 74% C 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.49 67% D+ 45% F
Price / Cash Flow Ratio -9.01 64% D 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -49.12% 64% D 24% F
Return on Invested Capital -235.05% 7% F 3% F
Return on Assets -18.48% 73% C 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.40 25% F 14% F
Short Percent 18.19% 11% F 12% F
Beta 1.99 26% F 14% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector